Kimmo Palin

Kimmo Palin

Auto-generated profile, based on publicly available information

Kimmo Palin

Applied Tumor Genomics Research Program, Research Programs Unit, University of Helsinki, Helsinki, Finland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Cell
Verified
Journal Article
Closed access
AJArttu Jolma
Arttu Jolma
JYJian Yan
Jian Yan
TWThomas Whitington
Thomas Whitington
JTJarkko Toivonen
Jarkko Toivonen
KNKazuhiro R. Nitta
Kazuhiro R. Nitta
JTJussi Taipale
Jussi Taipale

1 April 2010 in Nature
Verified
Journal Article
Open access
PDF file
WCWellcome Trust Case Control Consortium
Wellcome Trust Case Control Consortium
NCNick Craddock
Nick Craddock
MHMatthew E Hurles
Matthew E Hurles
NCNiall Cardin
Niall Cardin
RPRichard D Pearson
Richard D Pearson
PDPeter Donnelly
Peter Donnelly
Copy number variants (CNVs) account for a major proportion of human genetic polymorphism and have been predicted to have an important role in genetic susceptibility to common disease. To address this we undertook a large, direct genome-wide study of association between CNVs and eight common human diseases. Using a purpose-designed array we typed ∼19,000 individuals into distinct copy-number classes at 3,432 polymorphic CNVs, including an estimated ∼50% of all common CNVs larger than 500 base pairs. We identified several biological artefacts that lead to false-positive associations, including systematic CNV differences between DNAs derived from blood and cell lines. Association testing and follow-up replication analyses confirmed three loci where CNVs were associated with disease—IRGM for Crohn’s disease, HLA for Crohn’s disease, rheumatoid arthritis and type 1 diabetes, and TSPAN8 for type 2 diabetes—although in each case the locus had previously been identified in single nucleotide polymorphism (SNP)-based studies, reflecting our observation that most common CNVs that are well-typed on our array are well tagged by SNPs and so have been indirectly explored through SNP studies. We conclude that common CNVs that can be typed on existing platforms are unlikely to contribute greatly to the genetic basis of common human diseases.

1 June 2010 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
GWGong-Hong Wei
Gong-Hong Wei
GBGwenael Badis
Gwenael Badis
MBMichael F Berger
Michael F Berger
TKTeemu Kivioja
Teemu Kivioja
KPKimmo Palin
Kimmo Palin
JTJussi Taipale
Jussi Taipale
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

8 April 2010 in Genome Research
Verified
Journal Article
Open access
PDF file
AJArttu Jolma
Arttu Jolma
TKTeemu Kivioja
Teemu Kivioja
JTJarkko Toivonen
Jarkko Toivonen
LCLu Cheng
Lu Cheng
GWGong-Hong Wei
Gong-Hong Wei
JTJussi Taipale
Jussi Taipale
The genetic code—the binding specificity of all transfer-RNAs—defines how protein primary structure is determined by DNA sequence. DNA also dictates when and where proteins are expressed, and this information is encoded in a pattern of specific sequence motifs that are recognized by transcription factors. However, the DNA-binding specificity is only known for a small fraction of the ∼1400 human transcription factors (TFs). We describe here a high-throughput method for analyzing transcription factor binding specificity that is based on systematic evolution of ligands by exponential enrichment (SELEX) and massively parallel sequencing. The method is optimized for analysis of large numbers of TFs in parallel through the use of affinity-tagged proteins, barcoded selection oligonucleotides, and multiplexed sequencing. Data are analyzed by a new bioinformatic platform that uses the hundreds of thousands of sequencing reads obtained to control the quality of the experiments and to generate binding motifs for the TFs. The described technology allows higher throughput and identification of much longer binding profiles than current microarray-based methods. In addition, as our method is based on proteins expressed in mammalian cells, it can also be used to characterize DNA-binding preferences of full-length proteins or proteins requiring post-translational modifications. We validate the method by determining binding specificities of 14 different classes of TFs and by confirming the specificities for NFATC1 and RFX3 using ChIP-seq. Our results reveal unexpected dimeric modes of binding for several factors that were thought to preferentially bind DNA as monomers.

28 October 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TCThe Wellcome Trust Case Control Consortium
The Wellcome Trust Case Control Consortium
JMJulian B Maller
Julian B Maller
GMGilean McVean
Gilean McVean
JBJake Byrnes
Jake Byrnes
DVDamjan Vukcevic
Damjan Vukcevic
PDPeter Donnelly
Peter Donnelly

8 June 2015 in Nature Genetics
Verified
Journal Article
Closed access
RKRiku Katainen
Riku Katainen
KDKashyap Dave
Kashyap Dave
EPEsa Pitkänen
Esa Pitkänen
KPKimmo Palin
Kimmo Palin
TKTeemu Kivioja
Teemu Kivioja
LALauri A Aaltonen
Lauri A Aaltonen